Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Six Patent Applications Related to RNAi: Dec 7, 2006

Premium
Title: R2D2: An Enzyme of RNA Silencing
 
Number: 7,144,714
 
Filed: Sept. 25, 2003
 
Lead Inventor: Xiaodong Wang, University of Texas
 
According to its abstract, the patent covers “methods for making siRNA [by] recombinantly co-expressing a Dicer protein with an R2D2 protein to form a complex comprising the R2D2 protein and the Dicer protein, and contacting the complex with a double-stranded RNA under conditions wherein the complex cleaves the dsRNA into siRNA. The R2D2 protein may be a Drosophila R2D2 protein and the Dicer protein may be a Drosophila Dicer-2 protein. The Dicer protein and the R2D2 protein may be co-expressed in insect cells, such as S2, Sf9 or Hi5 cells, using a baculovirus expression system.”
 

 
Title: Insect Resistance Using Inhibition of Gene Expression
 
Number: 20060272049
 
Filed: Nov. 17, 2004 PCT Filed: Nov. 17, 2004   
 
Lead Inventor: Peter Michael Waterhouse, CSIRO Plant Industry
 
“The current invention provides methods to silence insect genes by using unpackaged dsRNA or siRNA, in one embodiment such dsRNA or siRNA is present in plant vascular tissue, preferably phloem, more particularly phloem sap, and the insect is a plant sap-sucking insect,” the patent application’s abstract states. “Also provided are DNA sequences which when transcribed yield a double-stranded RNA molecule capable of reducing the expression of an essential gene of a plant sap-sucking insect, methods of using such DNA sequences and plants or plant cells transformed with such DNA sequences. Also provided is the use of cationic oligopeptides that facilitate the entry of dsRNA or siRNA molecules in insect cells, such as plant sap-sucking insect cells.”
 

 
Title: RNA Interference-Mediated Treatment of Polyglutamine Repeat Expansion Diseases Using Short Interfering Nucleic Acid
 
Number: 20060270623
 
Filed: June 9, 2006
 
Inventor: James McSwiggen, Sirna Therapeutics
 
The invention, the patent application’s abstract states, “concerns compounds, compositions, and methods for the study, diagnosis, and treatment of diseases and conditions associated with polyglutamine repeat (polyQ) allelic variants that respond to the modulation of gene expression and/or activity. The … invention also concerns compounds, compositions, and methods relating to diseases and conditions associated with polyglutamine repeat allelic variants that respond to the modulation of expression and/or activity of genes involved in polyQ repeat gene expression pathways or other cellular processes that mediate the maintenance or development of polyQ repeat diseases and conditions such as Huntington’s disease and related conditions such as progressive chorea, rigidity, dementia, and seizures, spinocerebellar ataxia, spinal and bulbar muscular dystrophy, dentatorubropallidoluysian atrophy, and any other diseases or conditions that are related to or will respond to the levels of a repeat expansion protein in a cell or tissue, alone or in combination with other therapies,” the abstract adds. “Specifically, the invention relates to small nucleic acid molecules … capable of mediating RNA interference against the expression disease related genes or alleles having polyQ repeat sequences.”
 

 
Title: Inhibition of Hair Growth with RNAi Targeting Desmoglein 4 and Nude mRNAs
 
Number: 20060270621
 
Filed: Oct. 17, 2005
 
Inventor: Angela Christiano, Columbia University (Sirna Therapeutics)
 
The patent application, its abstract states, covers “methods for inhibition of desmoglein 4 and nude protein mRNA using RNA interference … in particular methods for inhibition or hair growth or hair removal. Also [covered] are nucleic acid constructs for RNAi-mediated inhibition of desmoglein 4 and nude protein mRNA and compositions including such constructs.”
 

 
Title: Novel Diagnosis and Treatment Tools for Cancer Using the NRIP Antibody and RNA Interference
 
Number: 20060269967
 
Filed: May 27, 2005
 
Lead Inventor: Show-Li Chen, National Defense University, Taiwan
 
According to the patent application’s abstract, “the invention provides an isolated nucleic acid encoding NRIP (Nuclear Receptor Interaction Protein) gene that is highly expressed in tumorigenic development of human neoplasms in cervical cancer. The invention provides an antibody against the NRIP protein, and methods of diagnosing the NRIP related cancer. The invention also features RNA interferences of the NRIP gene, and the methods of treatment for the NRIP related cancer using the RNA interference.”
 

 
Title: RNA Interference Compositions and Methods
 
Number: 20060269530
 
Filed: Feb. 23, 2004
 
Lead Inventor: Gary Clawson, Penn State University
 
The invention, the patent application’s abstract states, covers “isolated nucleic acids. For example, the invention provides isolated nucleic acids having at least one strand with both sense and antisense sequences that are complementary to each other. The invention also provides isolated nucleic acids having at least one strand that is a template for both sense and antisense sequences that are complementary to each other,” the abstract states. “In addition, the invention provides cells, viruses, and transgenic animals (e.g., transgenic non-human animals) containing one or more of the isolated nucleic acids provided herein as well as methods for using one or more of the isolated nucleic acids provided herein to reduce the level of an RNA (e.g., an mRNA) within a cell.”
 

 
Title: Small Interference RNA Gene Therapy
 
Number: 20060269518
 
Filed: Jan. 15, 2004 PCT Filed: Jan. 15, 2004
 
Lead Inventor: Lung-Ji Chang, University of Florida
 
“Gene expression is inhibited in a cell by introducing into the cell a lentiviral vector encoding a siRNA specific for the gene,” the patent application’s abstract states. “Lentiviral vectors encoding siRNA specific for a cancer-associated gene inhibited expression of the gene and caused cell death after being introduced into cancer cells. Viral replication in HIV-infected cells was inhibited after introducing a lentiviral vector encoding siRNA specific for HIV genes in into the cells.”